<DOC>
	<DOCNO>NCT03018730</DOCNO>
	<brief_summary>This open label switch study assess safety efficacy PRX-102 . Patients treat agalsidase alfa least 2 year stable dose ( &gt; 80 % labelled dose/kg ) least 6 month . Patients screen evaluated 3 month continue agalsidase alfa . Following screening period , patient enrol switched agalsidase alfa treatment receive intravenous ( IV ) infusions PRX-102 1 mg/kg every two week 12 month . No 25 % treated patient female .</brief_summary>
	<brief_title>Safety Efficacy PRX 102 Patients With Fabry Disease Currently Treated With REPLAGAL® ( Agalsidase Alfa )</brief_title>
	<detailed_description />
	<mesh_term>Fabry Disease</mesh_term>
	<criteria>1 . Age : 1860 year 2 . A documented diagnosis Fabry disease 3 . Males : plasma and/or leucocyte alpha galactosidase activity ( activity assay ) less low limit normal accord laboratory range one characteristic feature Fabry disease i. Neuropathic pain ii . Cornea verticillata iii . Clustered angiokeratoma 4 . Females : historical genetic test result consistent Fabry mutation , case novel mutation first degree male relative Fabry disease , one characteristic feature Fabry disease i. Neuropathic pain ii . Cornea verticillata iii . Clustered angiokeratoma 5 . Treatment agalsidase alfa least 2 year stable dose ( &gt; 80 % labelled dose/kg ) least 6 month 6. eGFR ≥ 40 ml/min/1.73 m2 CKDEPI equation 7 . Availability least 2 historical serum creatinine evaluation since start agalsidase alfa treatment 2 year 8 . Female patient male patient whose copartner childbearing potential agree use medically acceptable method contraception , include rhythm method 1 . History anaphylaxis Type 1 hypersensitivity reaction agalsidase alfa 2 . History renal dialysis transplantation 3 . History acute kidney injury 12 month prior screen , include specific kidney disease ( e.g. , acute interstitial nephritis , acute glomerular vasculitic renal disease ) ; nonspecific condition ( e.g , ischemia , toxic injury ) ; well extrarenal pathology ( e.g. , prerenal azotemia , acute postrenal obstructive nephropathy ) 4 . Angiotensin convert enzyme ( ACE ) inhibitor angiotensin receptor blocker ( ARB ) therapy initiate dose change 4 week prior screen 5 . Urine protein creatinine ratio ( UPCR ) &gt; 0.5 g/g treat ACE inhibitor ARB 6 . Known history hypersensitivity Gadolinium contrast agent 7 . Females pregnant , plan become pregnant study , breast feeding 8 . Cardiovascular event ( myocardial infarction , unstable angina ) 6 month period screen 9 . Congestive heart failure NYHA Class IV 10 . Cerebrovascular event ( stroke , transient ischemic attack ) 6 month period screen 11 . Presence medical , emotional , behavioral psychological condition , judgment Investigator and/or Medical Director , would interfere patient 's compliance requirement study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>